Sunshine Biopharma, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. Although the request identifies 2016 Q4, this filing is an annual report and does not provide separate fourth-quarter financial results. Unless otherwise stated, amounts below are U.S. dollars.
Business context
The company is a development-stage pharmaceutical business with two principal initiatives: proprietary cancer-drug development, led by Adva-27a, and a planned generic-drug business in Canada. In 2016, it secured worldwide rights to Adva-27a through a related-party patent transaction settled with common shares. It also obtained rights to market four generic drugs, but had not yet obtained the required Canadian establishment license or product identification numbers.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $1,708 |
| Operating expenses | $993,108 | $781,985 |
| Loss from operations | $993,108 | $780,277 |
| Net loss | $3,496,687 | $1,652,908 |
| Net cash used in operations | $314,182 | $867,644 |
| Cash and cash equivalents at year-end | $57,453 | $50,798 |
| Total liabilities | $274,104 | $1,270,306 |
- Gross margin is not meaningful because the company reported no 2016 revenue and no cost of revenue. The filing does not provide a clear gross-margin measure.
- Operating expenses increased $211,123. Management attributed much of the increase to consulting and officer/director compensation, partly offset by lower legal and licensing costs.
- The 2016 net loss included $1,945,898 of losses on debt conversions and a $556,120 impairment of Adva-27a patents. Interest expense was $34,732, compared with $307,211 in 2015.
- Cash flow from investing activities was a $3,439 outflow; financing activities provided $324,622. The company reported a $57,453 year-end cash balance.
- Current assets were $58,460 versus current liabilities of $274,104, implying a working-capital deficit of $215,644. There were no long-term liabilities reported at year-end. Current liabilities included $69,939 of notes payable and $167,032 of related-party notes payable.
- Shareholders’ equity was a deficit of $209,700. Common shares outstanding rose from 198.3 million at year-end 2015 to 769.4 million at year-end 2016; the filing reports 851.9 million outstanding as of April 12, 2017.
Material changes and notable transactions
- The company issued approximately 321.3 million shares in July 2016 to settle $835,394 of amended patent-purchase notes with Advanomics, a related party. It states that this completed its acquisition of worldwide Adva-27a rights. The patent carrying value was subsequently impaired to zero.
- During 2016, the company issued 411.8 million shares for debt and interest conversions, 146.75 million shares for services, and 12.6 million shares for cash. These conversions and related charges contributed substantially to reported losses and dilution.
- The four generic products are anastrozole, letrozole, bicalutamide and finasteride. The company was still pursuing Canadian approvals and a suitable facility; it could not estimate when the necessary approvals would be received.
- A 2015 lawsuit against JMJ Financial was settled in the first quarter of 2016, resulting in a one-time $25,000 payment to the company.
Outlook, risks and contingencies
- Funding and going concern: The auditor and management cited substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative operating cash flow and limited cash. Management estimated it would need approximately $6 million to implement its plans—$1 million for generics and $5 million for proprietary development—but reported no binding financing commitment.
- Adva-27a development: Clinical development had been delayed for lack of funds. Management anticipated Phase I trials beginning in mid-2018, subject to financing, and estimated an 18-month trial period. The company had made no FDA or other regulatory filings; trial timing, regulatory fast-track treatment and any compassionate-use marketing are uncertain.
- Manufacturing dispute: A pilot manufacturing run by Lonza produced a yield management said was significantly below expectations. Lonza required $687,818 before further work; the parties had not resolved their disagreement as of the report date. The filing provides no clear quantified estimate of potential litigation exposure.
- Generic launch and competition: Revenue depends on securing Health Canada approvals, facility licensing, financing and successful commercialization in a competitive market. The company also undertook to pay a 5% royalty on net sales of anastrozole for three years from its first sale.
- Related parties and governance: Advanomics is connected to company leadership, and the CEO provided a secured, convertible loan. The company disclosed that none of its directors were independent and that it had no board committees or adopted code of ethics.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective, citing staffing, accounting, transaction-review and period-end reporting deficiencies. The auditor issued an unqualified opinion on the financial statements, but highlighted the going-concern uncertainty and did not audit internal controls.
- No formal financial guidance was provided. The company stated it did not anticipate dividends in the foreseeable future.
Important facts for investors to verify
- Current cash runway, financing availability and the terms and potential dilution of new debt or equity funding.
- Status of the Health Canada establishment license and product identification numbers, and whether any generic products have launched or generated revenue.
- Resolution and financial consequences of the Lonza manufacturing-yield dispute, including whether further Adva-27a manufacturing is feasible.
- Adva-27a regulatory and clinical progress, financing needs, and support for management’s proposed trial timetable and potential market access.
- Outstanding and subsequently converted notes, related-party loan terms, share counts and the effect of discounted conversion provisions on dilution.
- Related-party patent acquisition terms, management conflicts and the basis for the patent impairment to zero.
- Reconciliation of apparent filing inconsistencies: the narrative reports 2015 investing cash outflow of $623,603 while the cash-flow statement shows $623,303; the cash-flow statement also gives a 2015 net-loss figure that differs from the statement of operations.